-
ALEXANDRA/IMpassion030
GLOBAL ALEXANDRA/IMpassion030
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANEBASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER
- Status
- No Longer Recruiting
- Objectives
-
1. Compare and evaluate effectiveness for TNBC patients with Atezolizumab as postoperative therapy + T-AC / EC vs T-AC / EC only
2. Evaluate the effectiveness of AtezoliZumab as adjuvant therapy + T–AC/EC vs T–AC/EC only
- Subjects
- Endpoints
- iDFS, OS, RFI, DRFI, DFS,
- Trial Period
-
Aug 2018 - 7years after final randomization
- Lead Principal Investigator
- (Japan) Dr. Shigehira Saji (Fukushima Medical Univ)
- Target Sample Size
- (Global) 2300, (Japan) 200
- Regimen
- Atezolizmab（RO5541267）
- Source of Funding
- BIG, F. Hoffman-La Roche Ltd. , Chugai
- Conference Presentation
- Articles and Publications
- Memo
- COI Disclosure